Innoviva (INVA) vs Nanobiotix S.A. (NBTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nanobiotix S.A. (NBTX) has outperformed Innoviva (INVA) over the past year, gaining 26.6% versus a loss of 12.2%. Over five years, NBTX leads with a +214.0% price change compared with +8.8% for INVA. Nanobiotix S.A. is the larger company by market cap ($1.35 billion vs $1.31 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INVA | NBTX |
|---|---|---|
| Share price | $18.41 | $26.50 |
| Market cap | $1.31B | $1.35B |
| 1-day change | 0.00% | -2.98% |
| YTD return | -7.90% | +14.62% |
| 1-year return | -12.17% | +26.61% |
| 5-year return | +8.81% | +213.98% |
| P/E ratio (TTM) | 7.83 | — |
| Forward P/E | 8.33 | — |
| EPS (TTM) | $2.35 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $411.33M | — |
| Revenue growth (YoY) | +14.67% | — |
| Net income (latest FY) | $271.17M | — |
| Gross margin | 74.80% | — |
| Operating margin | 39.81% | — |
| Net margin | 65.92% | — |
| 52-week high | $25.15 | $57.14 |
| 52-week low | $18.19 | $19.14 |
| Distance from 52-week high | -26.80% | -53.62% |
| Analyst consensus | buy | none |
| Avg. price target upside | +89.03% | +101.06% |
| Average volume | 865.66K | 148.94K |
| Shares outstanding | 71.08M | 50.95M |
| Employees | 159 | 98 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NBTX has outperformed INVA by 38.8 percentage points over the past year.
About Innoviva
INVA stock →Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
INVA vs NBTX FAQ
Which is bigger, Innoviva or Nanobiotix S.A.?
Nanobiotix S.A. (NBTX) is larger, with a market capitalization of $1.35B compared with $1.31B for Innoviva (INVA).
Which stock has performed better over the past year, INVA or NBTX?
NBTX returned +26.61% over the past 12 months, compared with -12.17% for INVA (price return, excluding dividends). Past performance does not predict future results.
Are Innoviva and Nanobiotix S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.